* Oric Pharmaceuticals Inc reported a quarterly adjusted loss of 49 cents per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -44 cents. The mean expectation of twelve analysts for the quarter was for a loss of 48 cents per share. Wall Street expected results to range from -52 cents to -38 cents per share.
* Reported revenue was zero; analysts expected zero.
* Oric Pharmaceuticals Inc's reported EPS for the quarter was a loss of 49 cents.
* The company reported a quarterly loss of $34.57 million.
* Oric Pharmaceuticals Inc shares had risen by 0.1% this quarter and gained 11.5% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 0.9% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 12 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "strong buy"
Wall Street's median 12-month price target for Oric Pharmaceuticals Inc is $19.00 This summary was machine generated from LSEG data November 13 at 02:18 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.48 -0.49 Missed
Jun. 30 2024 -0.41 -0.45 Missed
Mar. 31 2024 -0.44 -0.37 Beat
Dec. 31 2023 -0.49 -0.49 Met
Comments